New antibody drug conjugates can transform early HER2-positive breast cancer treatmen

[News]

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents-antibody-drug conjugates (ADCs)-can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.

More... (https://www.news-medical.net/news/20251018/New-antibody-drug-conjugates-can-transform-early-HER2-positive-breast-cancer-treatment.aspx)